Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 595-601

  Barnett, Mitchell J ^a,b   Wehring, Heidi ^b   Perry, Paul J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL OBSERVATION; DATA BASE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; COMPARATIVE STUDY; FACTUAL DATABASE; GOVERNMENT; KAPLAN MEIER METHOD; MEDICARE; METHODOLOGY; MULTIVARIATE ANALYSIS; ORGANIZATION AND MANAGEMENT; RISK FACTOR; STATISTICS; UNITED STATES; VETERAN;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATABASES, FACTUAL; DEMENTIA, VASCULAR; DIBENZOTHIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MEDICARE PART A; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; RISPERIDONE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 39649086952     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31815a2531     Document Type: Article

References (34)

1. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. Am J Geriatr Psychiatry. 2004;12:437-439.
2. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychol. 2003;64:134-143.
3. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc. 2006;54:354-361.
4. Wancata J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2004;16:107-115.
5. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.
6. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
7. Jeste DV, Dolder CR, Nayak GV, et al. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harv Rev Psychiatry. 2005;13:340-351.
8. Alexopoulos GS, Jeste DV, Chung H, et al. The Expert Consensus Guideline Series: Treatment of Dementia and Its Behavioral Disturbances. Minneapolis, MN: McGraw-Hill Co; 2005;1-111.
9. Nasrallah HA, Mahadik S, Evans D, et al. Are SGAs neuroprotective? Evidence from animal and human studies. Biol Psychiatry. 2002; 51(suppl 8S):25.
10. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;17:1395.
11. Cavazzoni P, Young C, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. Proceedings of the 44th Annual New Clinical Drug Evaluation Unit; Jun 1-4, 2004; Phoenix.
12. Committee on Safety of Medications. Summary of clinical trial data on cerebrovascular adverse events (CVAEs). Committee on Safety of Medicines Annual Report for 2004. Antipsychotics and Stroke:21-22. Available at: http://www.mhra.gov.uk. Accessed April 20, 2007.
13. Herrmann N, Lanctot K. Do SGAs cause stroke? CNS Drugs. 2005;19:91-103.
14. Herrmann N, Muhammad M, Lancet K. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113-1115.
15. Gill SS, Rochon PA, Herrmann N, et al. SGA drugs and risk of ischaemic stroke: population-based retrospective cohort study. BMJ. 2005;26:445.
16. Layton D, Harris S, Wilton LV, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19:473-482.
17. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17:1-13.
18. Lamoreauz J. The organizational structure for medical information management in the Department of Veterans Affairs: an overview of major health care databases. Med Care. 1996;34(suppl):MS31-MS45.
19. Beattie MC, Swindle, RW, Tomko LA, et al. Department of VA Databases Resource Guide: Volume II: Patient Treatment File. HSR and D Center for Health Care Evaluation, Department of Veterans Affairs Medical Center, Palo Alto, CA; 1996.
20. VHA Decision Support System (DSS) Documentation. Available at: http://www.virec.research.va.gov/DataSourcesName/DSS/DSSdocumentation. htm. Accessed July 7, 2006.
21. Smith MA, Doliszny KM, Shahar E, et al. Delayed hospital arrival for acute stroke: the Minnesota stroke survey. Ann Intern Med. 1998;129:190-196.
22. Smith MA, Shahar E, McGovern PG, et al. HMO Membership and patient age and the use of specialty care for hospitalized patients with acute stroke: the Minnesota stroke study. Med Care. 1999;37:1186-1198.
23. Allison PD. Estimating Cox regression models with PROC PHREG. In Survival Analysis Using the SAS System. 4th ed. Cary: SAS Institute, Inc; 2000:111-184.
24. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care. 2004;42:355-360.
25. Katz MH, Hauck WW. Proportional hazards (Cox) regression. J Gen Intern Med. 1993;8:702-711.
26. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161-1167.
27. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med. 2005;165:696-701.
28. Barnett MJ, Perry PJ, Alexander B, et al. Risk of mortality in associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol. 2006;26:1-6.
29. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
30. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294:1934-1943.
31. Rosenthal GE, Kaboli PJ, Barnett MJ. Differences in length of stay in Veterans Health Administration and other United States hospitals: is the gap closing? Med Care. 2003;41:882-894.
32. Kaboli PJ, Barnett MJ, Fuehrer SM, et al. Length of stay as a source of bias in comparing performance in VA and private sector facilities: lessons learned from a regional evaluation of intensive care outcomes. Med Care. 2001;39:1014-1024.
33. Iezzoni LI. The risks of risk adjustment. JAMA. 1997;278:1600-1607.
34. Kaboli PJ, McClimon B, Hoth A, et al. Assessing the accuracy of computerized medication history in VA patients. Am J Manag Care. 2004;11:872-877.